HORSHAM, Pa.--(BUSINESS WIRE)--Nucleonics, Inc., a privately held biotechnology company focused on the development of novel RNA interference (RNAi)-based therapeutics, announced today the appointment of health care industry veteran Michael D. Young, MD, Ph.D., MBA as chief medical officer. Dr. Young joins the company with more than 30 years of experience in the field of clinical research and pharmaceutical development, personally managing the development and submission of marketing applications for over a dozen new products as well as numerous supplemental applications.
